Table 1 Clinicopathological characteristics of patients with SCRC and PCRC

Sex (%)

 Female

564 (36.29)

126 (29.86)

438 (38.69)

 Male

990 (63.71)

296 (70.14)

694 (61.31)

EOCRC or LOCRC (%)

 LOCRC

1233 (79.34)

358 (84.83)

875 (77.30)

 EOCRC

321 (20.66)

64 (15.17)

257 (22.70)

Age (yrs) (median [IQR])

61.00 [52.00, 68.00]

63.00 [55.00, 70.75]

60.00 [51.00, 68.00]

Family history of tumours (%)

 No

1497 (96.33)

399 (94.55)

1098 (97.00)

 Yes

57 (3.67)

23 (5.45)

34 (3.00)

BMI (kg/m²) (%)

 18.5 to 24

927 (59.65)

252 (59.72)

675 (59.63)

 < 18.5

152 (9.78)

48 (11.37)

104 (9.19)

 ≥ 24

475 (30.57)

122 (28.91)

353 (31.18)

Hemoglobin (g/L) (%)

 > 110

1063 (68.40)

259 (61.37)

804 (71.02)

 ≤ 100

491 (31.60)

163 (38.63)

328 (28.98)

Platelet counts (10⁹/L) (%)

 ≤ 300

1122 (72.20)

289 (68.48)

833 (73.59)

 > 300

432 (27.80)

133 (31.52)

299 (26.41)

WBC (10⁹/L) (%)

 ≤ 10

1441 (92.73)

388 (91.94)

1053 (93.02)

 > 10

113 (7.27)

34 (8.06)

79 (6.98)

CEA (ng/mL) (%)

 ≤ 10

1157 (74.45)

297 (70.38)

860 (75.97)

 > 10

397 (25.55)

125 (29.62)

272 (24.03)

CA199 (kU/L) (%)

 ≤ 27

1225 (78.83)

320 (75.83)

905 (79.95)

 > 27

329 (21.17)

102 (24.17)

227 (20.05)

CA125 (kU/L) (%)

 ≤ 35

1428 (91.89)

383 (90.76)

1045 (92.31)

 > 35

126 (8.11)

39 (9.24)

87 (7.69)

CA153 (kU/L) (%)

 ≤ 25

1526 (98.20)

415 (98.34)

1111 (98.14)

 > 25

28 (1.80)

7 (1.66)

21 (1.86)

AFP (ng/mL) (%)

 ≤ 7

1488 (95.75)

402 (95.26)

1086 (95.94)

 > 7

66 (4.25)

20 (4.74)

46 (4.06)

Type of ascites (%)

 No

1453 (93.50)

389 (92.18)

1064 (93.99)

 Serous

90 (5.79)

30 (7.11)

60 (5.30)

 Bloody

11 (0.71)

3 (0.71)

8 (0.71)

Tumor location (%)

 Right colon

321 (20.66)

81 (19.19)

240 (21.20)

 Left colon

436 (28.06)

93 (22.04)

343 (30.30)

 Rectum

659 (42.41)

110 (26.07)

549 (48.50)

 Multiple segment

138 (8.88)

138 (32.70)

0 (0.00)

Radical or palliative surgery (%)

 Palliative

185 (11.90)

61 (14.45)

124 (10.95)

 Radical

1369 (88.10)

361 (85.55)

1008 (89.05)

(y)pTNM staging (%)

 0–I

205 (13.19)

51 (12.09)

154 (13.60)

 II

572 (36.81)

130 (30.81)

442 (39.05)

 III

533 (34.30)

152 (36.02)

381 (33.66)

 IV

244 (15.70)

89 (21.09)

155 (13.69)

Number of retrieved lymph nodes (%)

 < 12

165 (10.62)

26 (6.16)

139 (12.28)

 ≥ 12

1389 (89.38)

396 (93.84)

993 (87.72)

Gross classification (%)

 Mass type

583 (37.52)

168 (39.81)

415 (36.66)

 Infiltration type

13 (0.84)

6 (1.42)

7 (0.62)

 Ulceration type

958 (61.65)

248 (58.77)

710 (62.72)

Histological type (%)

 Classical adenocarcinoma

1452 (93.44)

391 (92.65)

1061 (93.73)

 Mucinous adenocarcinoma

97 (6.24)

29 (6.87)

68 (6.01)

 Signet ring cell carcinoma

5 (0.32)

2 (0.47)

3 (0.27)

Differentiation grade (%)

 Well differentiated

230 (14.80)

59 (13.98)

171 (15.11)

 Moderately differentiated

1096 (70.53)

293 (69.43)

803 (70.94)

 Poorly differentiated

228 (14.67)

70 (16.59)

158 (13.96)

Vessel invasion (%)

 Negative

1294 (83.27)

339 (80.33)

955 (84.36)

 Positive

260 (16.73)

83 (19.67)

177 (15.64)

Neural invasion (%)

 Negative

1243 (79.99)

339 (80.33)

904 (79.86)

 Positive

311 (20.01)

83 (19.67)

228 (20.14)

Ki67 expression (%)

 Low

95 (6.11)

28 (6.64)

67 (5.92)

 Moderate

204 (13.13)

60 (14.22)

144 (12.72)

 High

1255 (80.76)

334 (79.15)

921 (81.36)

MMR status (%)

 pMMR

1424 (91.63)

370 (87.68)

1054 (93.11)

 dMMR

130 (8.37)

52 (12.32)

78 (6.89)

Alive status (%)

 Alive

1293 (83.20)

338 (80.09)

955 (84.36)

 Death

261 (16.80)

84 (19.91)

177 (15.64)